inhibitor

(redirected from DPP-4 inhibitor)
Also found in: Thesaurus, Medical, Encyclopedia.

in·hib·i·tor

also in·hib·it·er  (ĭn-hĭb′ĭ-tər)
n.
One that inhibits, as a substance that retards or stops a chemical reaction.

inhibitor

(ɪnˈhɪbɪtə)
n
1. Also called: inhibiter a person or thing that inhibits
2. (Chemistry) Also called: anticatalyst a substance that retards or stops a chemical reaction. Compare catalyst
3. (Biochemistry) biochem
a. a substance that inhibits the action of an enzyme
b. a substance that inhibits a metabolic or physiological process: a plant growth inhibitor.
4. (General Physics) any impurity in a solid that prevents luminescence
5. (Astronautics) an inert substance added to some rocket fuels to inhibit ignition on certain surfaces

in•hib•i•tor

or in•hib•it•er

(ɪnˈhɪb ɪ tər)

n.
1. one that inhibits.
2. a substance that slows or stops a chemical reaction.
[1865–70]
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.inhibitor - a substance that retards or stops an activity
substance - a particular kind or species of matter with uniform properties; "shigella is one of the most toxic substances known to man"
angiotensin II inhibitor - an agent that retards or restrains the action of angiotensin II
antioxidant - substance that inhibits oxidation or inhibits reactions promoted by oxygen or peroxides
anticatalyst - (chemistry) a substance that retards a chemical reaction or diminishes the activity of a catalyst
moderator - any substance used to slow down neutrons in nuclear reactors
activator - (biology) any agency bringing about activation; a molecule that increases the activity of an enzyme or a protein that increases the production of a gene product in DNA transcription
Translations

in·hib·i·tor

n. inhibidor, agente que causa una inhibición;
fusion ______ de fusión.

inhibitor

n inhibidor m; angiotensin converting enzyme — inhibidor de la enzima convertidora de angiotensina; cholinesterase — inhibidor de la colinesterasa; fusion — inhibidor de (la) fusión; integrase — inhibidor de la integrasa; monoamine oxidase — inhibidor de la monoaminooxidasa; non-nucleoside reverse transciptase — (NNRTI) inhibidor no nucleósido de la transcriptasa inversa or reversa; nucleoside reverse transcriptase — (NRTI) inhibidor nucleósido de la transcriptasa inversa or reversa; nucleotide reverse transcriptase — (NtRTI) inhibidor nucleótido de la transcriptasa inversa or reversa; protease — inhibidor de la proteasa; proton pump — inhibidor de la bomba de protones; selective serotonin reuptake — inhibidor selectivo de la recaptación de serotonina
References in periodicals archive ?
The researchers found that persons newly receiving SGLT-2 inhibitors had 61 severe UTI events (incidence rate [IR] per 1,000 person-years, 1.76) compared with 57 events in the DPP-4 inhibitor group (IR, 1.77; hazard ratio, 0.98; 95 percent confidence interval, 0.68 to 1.41) in cohort 1.
The study assessed Tradjenta safety over the longest period ever studied in a DPP-4 inhibitor cardiovascular outcome trial, with a median follow-up of more than 6 years.
The study assessed linagliptin safety over the longest period ever studied in a DPP-4 inhibitor cardiovascular outcome trial, with a median follow-up of more than six years.
GLP-1RAs were reported to induce significant changes of fasting insulin level neither in patients with T2DM nor in healthy volunteers (51, 52); sitagliptin, a DPP-4 inhibitor, did not affect the fasting insulin level in obese prediabetic spontaneously hypertensive rats (53).
The goal of the study was to assess the difference in change in hemoglobin [A.sub.l,c] between real-world evidence and randomized-trial evidence after initiation of a GLP-1 RA or a DPP-4 inhibitor. In RCTs, GLP-1 RAs decreased [HbA.sub.l,c] by about 1.3% while DPP-4 inhibitors decreased [HbA.sub.l,c] by about 0.68% (i.e., DPP-4 inhibitors were about half as effective).
The National Institute for Health and Care Excellence (NICE) guidelines on T2DM management list both SGLT-2 inhibitors and DPP-4 inhibitors among the potential options for intensifying therapy after metformin.4 The American Association of Clinical Endocrinologists and the American College of Endocrinology guidelines do include a hierarchical recommendation to try a GLP-1 agonist first, followed by an SGLT-2 inhibitor, followed by a DPP-4 inhibitor, after metformin and lifestyle modifications--although the difference in strength of recommendations for these classes is noted to be small.
Four add-on treatment Groups 1-4 were pioglitazone, DPP-4 inhibitor, voglibose, and insulin (pre-mixed insulin [30% regular/70% NPH]), respectively, and received the second-line agents for a duration of 6 months or longer.
CVD-REAL 2 is a real-world, observational cohort study involving the analysis of health records for two matched cohorts of patients with T2DM from 12 countries across the globe, including 181,620 SGLT-2 inhibitor recipients and 181,620 DPP-4 inhibitor recipients who were newly initiated on their respective treatments between December 2012 and November 2017.
However, the DPP-4 inhibitor drugs were not associated with a reduced risk of mortality compared to people taking a placebo or no treatment at all.
To the best of our knowledge, the present ex vivo study is the first to demonstrate the suppressive effect of a DPP-4 inhibitor on foam cell formation in macrophages isolated from diabetic db/db mice and T2D patients.
Kihara et al., "DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study," Cardiovascular Diabetology, vol.
Developed DPP-4 inhibitor drugs increase the plasma concentrations of GIP and GLP-1 by preventing their degradation by inhibiting the pertinent enzyme (1, 2).